Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - From bench top to bedside

Current Vascular Pharmacology

Volumn 5, Issue 1, 2007, Pages 1-14

  Jackson Jr , Elias B ^a   Mukhopadhyay, Somnath ^a   Tulis, David A ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

BAY compounds; Carbon monoxide; Cyclic guanosine monophosphate; Nitric oxide; Phosphodiesterase; Protein kinase; Soluble guanylate cyclase; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 (4 CHLORO PHENYLSULFONYLAMINO) 4,5 DIMETHOXY N (4 (THIOMORPHOLINE 4 SULFONYL) PHENYL) BENZAMIDE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 3 AZIDO N [5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO [3,4 B]PYRIDINE 3 YL] 4 [6H] PYRIDINYL]BENZAMIDE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 5 CHLORO 2 (5 CHLORO THIOPHENE 2 SULFONYLAMINO N (4 (MORPHOLINE 4 SULFONYL) PHENYL) BENZAMIDE SODIUM SALT; BAY 519491; CARBON MONOXIDE; CFM 1571; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HMR 1766; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; S 3448; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; CARDIOVASCULAR AGENT; CELL RECEPTOR; GUANOSINE PHOSPHATE; SOLUBLE GUANYLYL CYCLASE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CELL FUNCTION; CONGESTIVE HEART FAILURE; DNA FLANKING REGION; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME REGULATION; HEART PROTECTION; HUMAN; HYPERTENSION; MITOGENESIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN HYDROLYSIS; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; REVIEW; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

5'-GUANYLIC ACID; ANIMALS; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GUANYLATE CYCLASE; HUMANS; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASCULAR DISEASES;

EID: 34247154034     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161110705010001     Document Type: Review

References (129)

1. Lincoln TM, Wu X, Sellak H, Dey N, Choi CS. Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Front Biosci 2006; 11: 356-67.
2. Costa ADT, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV, et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 2005; 97: 329-36.
3. Pilz RB, Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 2003; 93: 1034-46.
4. Melichar VO, Behr-Roussel D, Zabel U, Otto Uttenthal L, Rodrigo J, Rupin A, et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 2004; 101: 16671-76.
5. Wolfsgruber W, Feil S, Brummer S, Kuppinger O, Hofmann F, Feil R. A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cell. Proc Natl Acad Sci 2003; 100: 13519-24.
6. Feil R, Feil S, Hofmann F. A heretical view on the role of NO and cGMP in vascular proliferative diseases. Trends Mol Med 2005; 11: 71-5.
7. Davis KL, Martin E, Turko IV, Murad F. Novel effects of nitric oxide. Annu Rev Pharmacol Toxicol 2001; 41: 203-36.
8. Bian K, Murad F. Nitric oxide (NO) - biogeneration, regulation, and relevance to human diseases. Front Biosci 2003; 8: D264-78.
9. Raghavan SAV, Dikshit M. Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. Pharmacol Res 2004; 49: 397-414.
10. Parker JD. Nitrate tolerance, oxidative stress, and mitochondrial function: Another worrisome chapter on the effects of organic nitrates. J Clin Invest 2004; 113: 352-54.
11. Fung HL. Biochemical mechanism of nitroglycerin action and tolerance: Is this old mystety solved? Annu Rev Pharmacol Toxicol 2004; 44: 67-85.
12. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon on nitrate tolerance. Circ Res 2005; 97: 618-28.
13. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 1996; 15: 6863-68.
14. Feil R, Kemp-Harper B. cGMP signalling: From bench to bedside. EMBO Report 2006; 7: 149-53.
15. Boolell M, Allen MJ, Ballard SA; Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
16. Lincoln TM. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon? Mol Pharmacol 2004; 66: 11-13.
17. Bredt DS; Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351: 714-18.
18. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-66.
19. Cooke JP, Dzau VJ. Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
20. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endotheial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-12.
21. Andrews KL, Triggle CR, Ellis A. NO and the vasculature: Where does it come from and what does it do? Heart Fail Rev 2002; 7: 423-45.
22. Sharma VS, Magde D. Activation of soluble guanylate cyclase by carbon monoxide and nitric oxide: A mechanistic model. Methods 1999; 19: 494-505.
23. Ewing JF, Raju VS, Maines MD. Induction of heart heme oxygenase-1 (HSP32) by hyperthermia: Possible role in stress-mediated elevation of cyclic 3′:5′-guanosine monophosphate. J Pharmacol Exp Ther 1994; 271: 408-14.
24. Raju VS, Maines MD. Renal ischemia/reperfusion up-regulates heme oxygenase-1 (HSP32) expression and increases cGMP in rat heart. J Pharmacol Exp Ther 1996; 277: 1814-22.
25. McCoubrey Jr. WK, Huang TJ, Maines MD. Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 1997; 247: 725-32.
26. Russwurm M, Koesling D. Isoforms of NO-sensitive guanylyl cyclase. Mol Cell Biochem 2002; 230: 159-64.
27. Buechler WA, Nakane M, Murad F. Expression of soluble guanylate cyclase activity requires both enzyme subunits. Biochem Biophys Res Commun 1991; 174: 351-57.
28. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977; 3: 23-35.
29. Russwurm M, Behrends S, Harteneck C, Koesling D. Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem J 1998; 335: 125-30.
30. Koesling D. Studying the structure and regulation of soluble guanylyl cyclase. Methods 1999; 19: 485-93.
31. 1 isoform of soluble guanylyl cyclase by nitric oxide. J Clin Invest 1997; 100: 1488-92.
32. Stone JR, Marletta MA. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: Implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem Biol 1998; 5: 255-61.
33. Wedel B, Humbert P, Harteneck C, Foerster J, Malkewitz J, Bohme E, et al. Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci USA 1994; 91: 2592-96.
34. Zabel U, Kleinshnitz C, Oh P, Nedvestky P, Smolenski A, Muller H, et al. Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat Cell Biol 2002; 4: 307-11.
35. Agullo L, Garcia-Dorado D, Escalona N, Ruiz-Meana M, Mirabet M, Inserte J, et al. Membrane association of nitric oxide-sensitive guanylyl cyclase in cardiomyocytes. Cardiovasc Res 2005; 68: 65-74.
36. Russwurm M, Wittau N, Koesling D. Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. J Biol Chem 2001; 276: 44647-52.
37. Deinum G, Stone JR, Babcock GT, Marletta MA. Binding of nitric oxide and carbon monoxide to soluble guanylate cyclase as observed with Resonance raman spectroscopy. Biochem 1996; 35: 1540-47.
38. Francis SH, Blount MA, Zoraghi R, Corbin JD. Molecular properties of mammalian proteins that interact with cGMP: Protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Front Biosci 2005; 10: 2097-17.
39. Arts JD, Toader V, Zavorin SI, Bennett BM, Thatcher GRJ. In vitro activation of soluble guanylyl cyclase and nitric oxide release: A comparison of NO donors and NO mimetics. Biochemistry 2001; 40: 9256-64.
40. Clark JE, Naughton P, Shurey S, Green CJ, Johnson TR, Mann BE, et al. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ Res 2003; 93: E2-e8.
41. Foresti R, Hammad J, Clark JE, Johnson TR, Mann BE, Friebe A, et al. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br J Pharmacol 2004; 142: 453-60.
42. Motterlini R, Sawle P, Hammad J, Bains S, Alberta R, Foresti R, et al. CORM-A1: A new pharmacologically active carbon monoxide-releasing molecule. FASEB J 2005; 19: 284-6.
43. Sawle P, Foresti R, Mann BE, Johnson TR, Green CJ, Motterlini R. Carbon monoxide-releasing molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7 murine macrophages. Br J Pharmacol 2005; 1-11.
44. Tulis DA, Keswani AN, Peyton KJ, Wang H, Schafer AI, Durante W. Local administration of carbon monoxide inhibits neointima formation in balloon injured rat carotid arteries. Cell Mol Biol 2005; 51: 441-6.
45. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, Schafer AI. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun 2000; 279: 646-52.
46. Bohl MKS, Lipke EA, Rice EEH, Liel MS, Myler HA, Zygourakis C, et al. Nitric oxide-generating hydrogels inhibit neointima formation. J Biomater Sci Polym Ed 2005; 16: 659-72.
47. Hobbs AJ. Soluble guanylate cyclase: An old therapeutic target revisited. Br J Pharmacol 2002; 136: 637-40.
48. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84: 4226-33.
49. Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 1995; 116: 1973-8.
50. Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylate cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 1997; 120: 681-9.
51. Wegener JW, Gath I, Forstermann U, Nawrath H. Activation of soluble guanylate cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br J Pharmacol 1997; 122: 1523-9.
52. Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, et al. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylate cyclase. Br J Pharmacol 1999; 128: 1316-22.
53. Schmidt K, Schrammel A, Koesling D, Mayer B. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells. Mol Pharmacol 2001; 59: 220-4.
54. Yoshina S, Tanaka A, Kuo SC. [Studies on heterocyclic compounds. XXXIC. Synthesis of furo[3,2-c]pyrazole derivatives. (2). Electrophilic substitution of 1,3-diphenylfuro[3,2-c]pyrazole (author's transl)). Yakugaku Zasshi 1978; 98: 204-9.
55. Tulis DA. Salutary properties of YC-1 in the cardiovascular and hematological systems. Curr Med Chem 2004; 2: 343-59.
56. Chun YS, Yeo EJ, Park JW. Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett 2004; 207: 1-7.
57. Russwurm M, Koesling D. Guanylyl cyclase: NO hits its target. Biochem Soc Symp 2004; 71: 51-63.
58. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998; 53: 123-7.
59. Lee YC, Martin F, Murad F. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc Natl Acad Sci USA 2000; 97: 10763-68.
60. Russwurm M, Mergia E, Mullershausen F, Koesling D. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem 1002; 277: 24883-88.
61. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, et al. Effects of the soluble guanylate cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999; 127: 195-203.
62. Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997; 320: 161-6.
63. Tulis DA, Bohl MKS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, et al. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun 2002; 291: 1014-21.
64. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz F, Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 1998; 54: 962-7.
65. Becker EM, Schmidt P, Schramm M, Schroder H, Walter U, Hoenicka M, et al. The vasodilator-stimulated phosphoprotein (VASP): Target of YC-1 and nitric oxide effects in human and rat platelets. J Cardiovasc Pharmacol 2000: 35: 390-97.
66. Wang JP, Chang LC, Raung SI, Hsu MF, Huang LJ, Kuo SC. Inhibition of superoxide anion generation by YC-1 in rat neutrophils through cGMP-dependent and -independent mechanisms. Biochem Pharmacol 2002; 63: 577-85.
67. Brunetti M, Mascetra N, Manarini S, Martelli N, Cerletti C, Musiani P, et al. Inhibition of cGMP-dependent protein kinases potently decreases neutrophil spontaneous apoptosis. Biochem Biophys Res Commun 2002; 297: 498-501.
68. Hwang TL, Wu CC, Guh JH, Teng CM. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway. Biochem Pharmacol 2003; 66: 49-56.
69. McLaughlin BE, Chretien ML, Choi C, Brien JF, Makatsu K, Marks GS. Potentiation of carbon monoxide-induced relaxation of rat aorta by YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzylin-dazole]. Can J Physiol Pharmacol 2000; 78: 343-9.
70. Seitz S, Wegener JW, Rupp J, Watanabe M, Jost A, Gerhard R, et al. Involvement of K(+) channels in the relaxant effects of YC-1 in vascular smooth muscle. Eur J Pharmacol 1999; 382: 11-18.
71. Faraci FM, Sobey CG. Role of soluble guanylate cyclase in dilator responses of the cerebral microcirculation. Brain Res 1999: 821: 368-73.
72. Hsu HK, Juan SH, Ho PY, Liang YC, Lin CH, Teng CM, et al. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmacol 2003; 66: 263-71.
73. Lien JC, Lee FY, Huang LJ, Pan SL, Guh GH, Teng CM, et al. 1-benzyl-3-(5′-hydroxymethyl-2′-furyl)indazole (YC-1) derivatives as novel inhibitors against sodium nitroprusside-induced apoptosis. J Med Chem 2002; 45: 4947-49.
74. Taimor G, Hofstaetter B, Piper HM. Apoptosis induction by nitric oxide in adult cardiomyocytes via cGMP-signaling and its impairment after simulated ischemia. Cardiovasc Res 2000; 45: 588-94.
75. Bergemann C, Loken C, Becker C, Graf B, Hamidizadeh M, Fischer Y. Inhibition of glucose transport by cyclic GMP in cardiomyocytes. Life Sci 2001; 69: 1391-406.
76. Wu CH, Chang WC, Chang GY, Kuo SC, Teng CM. The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: An in vitro and in vivo study. J Pharmacol Sci 2004; 94: 252-60.
77. Ferrero R, Tones M. Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism. Neuropharm 2001; 41: 895-906.
78. Rice PL, Peters SL, Beard KS, Ahnen DJ. Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol Cancer Ther 2006; 5: 746-54.
79. Li L, Li H, Underwood T, Lloyd M, David M, Sperl G, et al. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharm Exp Ther 2001; 299: 583-92.
80. Liu YN, Pan SL, Peng CY, Guh JH, Huang DM, Chang YL, et al. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9.J Pharmacol Exp Ther 2006; 316: 35-41.
81. Pan SL, Guh JH, Peng CY, Wang SW, Chang YL, Cheng FC, et al. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharm Exp Ther 2005; 314: 35-42.
82. Teixeira CE, Priviero FBM, Webb RC. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylate cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridine-3-yl]purimidin-4-ylamine] and YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole]. J Pharmacol Exp Ther 2006; 317: 258-66.
83. Gonzalez-Luis G, Cogolludo A, Moreno L, Lodi F, Tamargo J, Perez-Vizcaino F, et al. Relaxant effects of the soluble guanylate cyclase activator and NO sensitizer YC-1 in piglet pulmonary arteries. Biol Neonate 2006; 90: 66-72.
84. Moreno L, Gonzalez-Luis G, Cogolludo A, Lodi F, Lopez-Farre A, Tamargo J, et al. Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. Am J Physiol Lung Cell Mol Physiol 2005; 288: L125-30.
85. Lindner AE, McClusky LP, Cole III KR, Lanning KM, Webb RC. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J Pharmacol Exp Ther 2005; 314: 9-15.
86. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410: 212-15.
87. Becker EM, Alonso-Alija C, Apeler H, Gerzer R, Minuth T, Pleib U, et al. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol 2001; 1: 13-24.
88. Koglin M, Stasch JP, Behrends S. BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase. Biochem Biophys Res Commun 2002; 292: 1057-62.
89. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001; 11: 781-84.
90. Straub A, Benet-Buchholz J, Frode R, Kern A, Kohlsdorfer C, Schmitt P, et al. Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2002; 10: 1711-17.
91. Bischoff E, Stasch JP. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. Circulation 2004; 110: E320.
92. Mullershausen F, Russwurm M, Friebe A, Koesling D. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 2004; 109: 1711-13.
93. Bischoff E, Stasch JP, Mullershausen F, Russwurm M, Friebe A, Koesling D. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. Circulation 2004; 110: E320-21 (Response).
94. Xu HL, Gavrilyuk V, Wolde HM, Baughman VL, Pelligrino DA. Regulation of rat pial arteriolar smooth muscle relaxation in vivo through multidrug resistance protein 5-mediated cGMP efflux. Am J Physiol Heart Circ Physiol 2004; 286: H2020-27.
95. Teixeira CE, Priviero FBM, Todd, Jr. J, Webb RC. Vasorelaxing effect of BAY 41-2272 in rat basilar artery: Involvement of cGMP-dependent and independent mechanisms. Hypertension 2006; 47: 596-602.
96. Priviero FB, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, Antunes E. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent solubly guanylate cyclase activator. Clin Exp Pharmacol Physiol 2005; 32: 728-34.
97. Bawankule DU, Sathishkumar K, Sardar KK, Chanda D, Krishna AV, Prakash VR, et al. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4- b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: Role of sodium pump. J Pharmacol Exp Ther 2005; 314: 207-13.
98. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, et al. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004; 110: 2253-59.
99. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006; 113: 286-95.
100. Deruelle P, Grover TR, Storme L, Abman SH. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2005; 288: L727-33.
101. Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006; 90: 135-44.
102. Hobbs AJ, Moncada S. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. Vasc Pharmacol 2003; 40: 149-54.
103. Boerrigter G, Costello-Boerrigter C, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003; 107: 686-89.
104. Wen JF, Cui X, Jin JY, Kim SM, Kim SZ, Kim SH, et al. High and low gain switches for regulation of cAMP efflux concentration: Distinct roles for particulate GC- and soluble GC-cGMP-PDE3 signaling in rabbit aorta. Circ Res 2004; 94: 936-43.
105. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 2004; 101: 1386-91.d
106. Schmidt P, Schramm M, Schroder H, Stasch JP. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 2003; 468: 167-74.
107. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, et al. Pharmacological actions of a povel NO-independent guanylyl cyclase stimulator, BAY 41-8543; in vitro studies. Br J Pharmacol 2002; 135: 333-43.
108. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 2002; 135: 344-55.
109. Selwood DL, Brummmell DG, Budworth J, Burtin GE. Camphell RO, Chana SS, et al. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem 2001; 44: 78-93.
110. Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, et al. A-350619: A novel activator of soluble guanylyl cyclase. Life Sci 2003; 72: 1015-25.
111. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Maerter M, et al. NO- and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002; 136: 773-83.
112. Wunder F, Stasch JP, Hutter J, Alonso-Alija C, Huser J, Lohrmann E. A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal Biochem 2005; 339: 104-12.
113. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 2004; 2779: 3025-32.
114. Witte K, Hachemberger J, Castell MF, Vahl CF, Haller C. Nitric oxide-sensitive soluble guanylyl cyclase activity is preserved in internal mammary artery of type 2 diabetic patients. Diabetes 2004; 53: 2640-44.
115. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, et al. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 2006; 69: 1260-68.
116. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109: 366-98.
117. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93: 280-91.
118. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003; 64: 533-46.
119. + channel. J Cardiovasc Pharmacol 2005; 46: 600-8.
120. ATP channels in rabbits. J Mol Cell Cardiol 2006, 40: 405-11.
121. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 1672: 105-13.
122. Zhu B, Strada S, Stevens T. Cyclic GMP- specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2005; 289: L196-206
123. 2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 2006; 98: 777-84.
124. Bornfeldt KE. Nuclear signaling in smooth muscle cells: Cyclic nucleotide phosphodiesterase 1A moves in. Circ Res 2006; 98: 720-22.
125. Corazza S, Scarabottolo L, Lohmer S, Liberati C. An innovative cell-based assay for the detection of modulators soluble guanylate cyclase. Assay Drug Dev Tech 2006; 4: 165-73.
126. Balashova N, Chang FJ, Lamothe M, Sun Q, Beuve A. Characterization of a novel type of endogenous activator of soluble guanylyl cyclase. J Biol Chem 2005; 280: 2186-96.
127. Hanafy KA, Martin E, Murad F. CCTη, a novel soluble guanylyl cyclase-interacting protein. J Biol Chem 2004; 279: 46946-53.
128. Venema RC, Venema VJ, Ju H, Harris MB, Snead C, Jilling T, et al. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am J Physiol Heart Circ Physiol 2003; 285: H669-78.
129. Diez-Marques ML, Ruiz-Torres MP, Griera M, Lopez-Ongil S, Saura M, Rodriquez-Puyol D, et al. Arg-Gly-Asp (RGD)-containing peptides increase soluble guanylate cyclase in contractile cells. Cardiovasc Res 2006; 69: 359-69.